Renal Cell Carcinoma Archives | MSD Oncology Clinical Trials

Study Keyword: Renal Cell Carcinoma

The purpose of this study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced disease progression on or after receiving prior therapy. Part 1 will establish the safety of belzutifan plus palbociclib and determine a recommended dosage of palbociclib for the combination therapy by ascending dose escalation. Part 2 will evaluate the efficacy and safety of belzutifan plus palbociclib at the dosage level determined in Part 1.

A Study of Belzutifan in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma

September 1, 2022

By Tyler Kalist

A Study of Belzutifan in Participants With Advanced Renal Cell Carcinoma

March 10, 2022

By Tyler Kalist

This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis

A Study of Belzutifan Versus Everolimus in Participants With Advanced Renal Cell Carcinoma

March 7, 2022

By clique_admin

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed